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A Method for Measuring Activated Factor Vlll
in Plasma
H. Kessels,  S. B6guin, R. Wagenvoord, and H. C. Hemker
From the Department of Biochemistry, University of Limburg, Maastricht, The Netherlands
Summary
A method is described which enables a quantitative measure-
rnent of the concentration of activated factor VIII (VIIIa) in
plasma. Based on the ability of factor VIIIa to accelerate the
activation of factor X by factor IXa, phospholipid and calcium
ions, the course of factor X activation in time is measured using a
chromogenic substrate. Free factor Xa is able to activate non-
activated factor VIII present in a plasma sample, which increases
the factor X activation velocity, and thus disturbs the measure-
ment of factor VIIIa. Furthermore, factor Xa was found to be
inactivated by serine protease inhibitors from the plasma sample.
By adding surplus chromogenic substrate these reactions of
factor Xa are inhibited and at the same time the rate of substrate
conversion is a measure of the amount of factor Xa present.
Factor X activation and amidolysis of chromogenic substrate then
take place simultaneously. It is shown that under proper condi-
tions the factor X activation velocity is linearly proportional to
the factor VIIIa concentration. This causes the optical density to
increase as a parabolic function of time. The concentration of
factor VIIIa can be obtained from the quadratic coefficient of the
equation describing the parabola. The method is specific for
factor VIIIa in that the extrinsic factor X activator is shown to
have no influence on the measurement of factor VIIIa in throm-
boplastin activated plasma. We conclude that a sensitive and
reliable method for assessing factor VIIIa concentrations in
plasma has been developed on the basis of simultaneous inhibi-
tion and measurement of factor Xa by a high concentration of
chromogenic substrate.
lntroduction
Clot formation in plasma is initiated by the serial enzymatic
activation of clotting factors, which results in the appearance of
small traces of thrombin (1). The explosive nature of the
coagulation process is a consequence of the positive feedback
reactions that these thrombin traces exert on the cofactors V
(2-4) and VIII (4-9), and on platelets, in case of platelet rich
plasma (10). Activated fact6rs V and VIII boost the performance
of factors Xa and IXa, whereas activated platelets provide,
among other things, the negatively charged surface necessary for
most coagulation reactions (1L).
As the line separating thrombosis and bleeding seems to be a
thin one, the importance of control mechanisms that steer the
hemostatic process is obvious. In spite of the enormous progress
that. has been made by studies in systems with purified clotting
factors, the fine tuning of hemostasis in vivo still remains a largely
unsolved riddle. The initial traces of thrombin and the feedback
reactions they provoke, are likely to play a crucial role in the
overall process of hemostasis. Therefore, we set out to develop a
method to assess directly one of those feedback reactions in
olasma. viz- the activation of factor VIII.
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Tiaditionally, factor VIII concentrations, and also factor VIII
activation in plasma were measured using coagulation assays,
involving VIII deficient plasma (12-17). The occurrence of vari-
ous feedback reactions made it impossible to relate, in a
quantitatively reliable way, obtained values to amounts of factor
VIII activated. The advent of a chromogenic substrate for
factor Xa made a more direct way of determining functional
factor VIIIa conceivable. The property of activated factor VIII,
to accelerate the activation of factor X by factor IXa, phos-
pholipid and calcium ions, by several orders of magnitude, was
molded into a sensitive assay procedure for VIIIa (16, t7).
However, feedback reactions of factor Xa on factor VIII (18-21)
and factor X (22), and the inactivation of factor Xa by the
antithrombin III and o1-antitrypsin present in plasma, can seri-
ously hamper the feasibility of using the same type of assay for the
measurement of factor VIIIa in plasma. On the basis of a method
by Pieters et al. (4) we developed a scheme for measuring
factor VIIIa in plasma, that circumvents these difficulties.
Materials and Methods
Materials. Factor Xa chromogenic substrate (CH3OCO-D-CHG-GIy-
Arg-pNA-AcOH) and thrombin inhibitor o-NAPAP (N-o-(2-Naphtylsul-
fonyl-glycyl)-D,L-Amidinophenyl-alanine-piperidine HCI) were obtained
from Pentapharm (Basel, Switzerland). o-NAPAP in a concentration of
L pM inhibits thrombin mediated amidolysis of factor Xa chromogenic
substrate for 99.50/", whereas factor Xa is inhibited no more than IT",
where thrombin concentration is 20 nM and factor Xa concentration
0 75 nM (23). Buffer used was 50 mM Tiis, 175 mM NaCl, 0.5 g/l
ovalbumin, pH 7 .9. All chemicals were to the highest grade commercially
available.
Proteins. Bovine factors X, Xa, IXa and IIa were purified as previously
described (2427).
Phospholipid. Phospholipid vesicles (PL) used were 80 mole-% egg
phosphatidyl choline and 20 mole-Y" brain phosphatidyl serine (Sigma).
They were prepared as described by Rosing et al. (28).
Preparation of plasma and euglobulins Plasma was prepared (29) from
blood from 12 healthy male donors, 9 volumes collected on 1 volume of
trisodium citrate (0.13 M). Plasma was defibrinated by mixing an aliquot
of plasma with 1/50 volume of reptilase reagent (Boehringer Mannheim),
letting a clot form for 5 min at 37" C and keeping the clotted plasma at
0" C for 10 min. The fibrin formed was discarded by winding on a small
plastic spatula. Euglobulins were prepared from plasma by precipitation
at low ionic strength, pH 5.2 (plasma diluted 1 in 20 in a 0.016 vol-%
acetic acid solution), on ice for 30 min. After centrifugation (10 min,
4,000 rpm, 4' C), they were resuspended in 5 volumes NaCl-aq (9 g/l) and
l volume trisodium citrate (0.13 M), so as to contain a concentration of
factor VIII that was not lower than 75"k . 10 nM factor Xa remains stable
in this solution for over t h, in the presence of 0.1 U/ml heparin.
Hemophilia A plasma was obtained from a single donor and it contained
less than 1-o/" factor VIII activity.
Human brain thromboplastin was prepared as described by Owren and
Aas (30). It was subsequently centrifuged at 1,000 rpm for 5 min and
stored in 50 pl aliquots at -80' C. It was thawed and diluted 1 in 18 with
buffer containing 167 mM CaCl2, then incubated at 37" C for t h, and
kept at room temperature.
Experimental conditions. Final concentrations of the reactants used
were: factor IXa: 100 nM, PL: 20 pM, Ca2+: 5 mM and factor X:
330 nM. These are described by Wagenvoord (23) to be optimal for
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factor X activation in a bovine system with human factor VIIIa. The same
holds fbr pH (7.9) and PS:PC ratio of the phospholipid vesicles (20180
mole/mole). A11 experiments were performed at 37" C.
Factor Xa assay 300 pl from a factor X activation mixture was
subsampled in372 1tl buffer containing 20 mM EDTA. This can be shown
to stop factor X activation instantaneously. After addition of 28 pl of the
chromogenic substrate for factor Xa, to a final concentration of 80 pM,
absorbance was read kinetically for 2 min. The factor Xa concentration
could be inferred from the initial linear increase in absorbance, using a
linear least squares fit procedure. All mixtures that were assayed for
factor Xa, contained 2.33 ytM cI-NAPAP, resulting in a final concentra-
tion of 1 pM, thereby blocking thrombin activity towards the chromogenic
substrate for factor Xa for more than 99To .
Measurement of absorbance. All photometry was carried out at 405 nm
in a sensitive dual wavelength photometer.
Results
Since factor VIIIa is not an enzyme, its functional concentra-
tion cannot be measured directly by way of a chromogenic
substrate. Instead, the ability of factor VIIIa to enhance factor X
activation by factor IXa, phospholipid, and Ca2+, must be
exploited. The concentration of factor Xa can be determined
chromogenically, which permits an estimation of the factor VIIIa
level.
Activation of Factor VIII by Factor Xa
It is long known that factor Xa is able to activate factor VIII,
be it less effectively than thrombin. Since in plasma, the medium
for which we intended to develop the factor VIIIa assay, both
activated and non-activated factor VIII may be present, this
feature of factor Xa is a potential hazard to the reliability of any
method.
The effect of factor Xa on the time course of factor X
activation was investigated by adding a small quantity of fac-
tor Xa to a mixture containins factors IXa and X. PS:PC
vesicles. Ca2* and non activatel plasma. Thrombin mediated
activation of factor VIII was prevented by the presence of the
thrombin inhibitor o-NAPAP. In case of factor Xa activation of
factor VIII, this will result in the formation of complete tenase,
the complex of factors IXa and VIIIa on a phospholipid surface,
which leads to an increase of the factor Xa concentration. When
factor Xa would not act on factor VIII, factor Xa concentration
wou ld  remain  una l te red .
Rather surprisingly, Fig. 1 shows an initial drop of the fac-
tor Xa concentration which is followed by an increase- When the
experiment was repeated with hemophilia A plasma, and with the
euglobulin fraction of normal plasma (no serine protease
inhibitors), either the downward or the upward bend of the curve
was found to disappear. Using buffer instead of plasma causes the
factor Xa concentration to remain constant.
Thus it seems likely that factor Xa indirectly causes factor X
activation by activating factor VIII, but also that factor Xa is
subject to inactivation by inhibitors (ATIII, o1 antitrypsin)
present in the diluted plasma. When the experiments were
repeated with a high concentration of hirudin (1.25 pM) instead
of o-NAPAP, a similar course of X activation was obtained
(results not shown).
Both effects, factor Xa mediated activation of factor VIII and
factor Xa inactivation directly affect the signal used for the
determination of factor Vllla. Because the measurement is based
on the ability of factor Xa to split chromogenic substrate, adding
a factor Xa inhibitor will be effective to inhibit these undesired
reactions, as well as the factor Xa measurement itself.
Inhibition of Factor Xa by Chromogenic Substrate
The only "inhibitor" that can dampen the side reactions
without influencing signal generation is the chromogenic substrate
for factorXa, at a concentration sufficiently above K-. This
would prevent all reactions of factor Xa but amidolysis of
chromogenic substrate. It means that factor X activation by the
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Fig.l Influence of factor Xa on factor X activation. To a mixture of
facror IXa (100 nM), PL (20 pM), Ca2+ (5 mM) and a-NApAp
(2.33 pM), factor X was added to a final concentration of 0.33 pM At
1 min, plasma (closed circles), hemophilia A plasma (open circles),
euglobulin fraction (open triangles) or buffer (closed triangles) were
diluted 1 in 30 in this mixture. One min later. factor Xa was added to a
final concentration of 1 nM. At intervals 300 pl were taken from this
mixture for assay of factor Xa, as described in the materials and methods
sectlon
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Fig.2 Stabilization of factor VIIIa. Plasma was diluted 100 fold in a
cuvette containing IXa (100 nM), PL (20 pM) and Ca2* (5 mM). At 30 s
thrombin was added to concentrations of 100 nM (closed circles, mean of
thrce experiments) or 200 nM (open triangles). At various times hereaf-
ter, chromogenic substrate for factor Xa (400 pM) and o-NAPAP (1 pM)
were added. The course of absorbance in timc was measured uoon
addition of factor X (0.33 pM), 10 s later On the vertical axis are rhe
values of the quadratic cocfficient (QC) of the equation describing the
absorbance time curves (.%.kz.f ([VIIIa]), see eq. III). They were
obtained using a quadratic least squares fit procedure As wc were not
able to determinc the course of factor VIII activation during the first 5 s
after thrombin addition, the curve shown is putative and plotted as a
dotted line
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.Frg 3 Proportionality of the factor X activation velocity to the concen-
tration of factor VIIIa At time zero, plasma, containing various concen-
trations of factor VIII, was diluted 100 fold in a cuvettc containins IXa
{1{.t0 nM). PL (20 pM) and Ca2+ (5 mM). At 30 s thrombin was added, to
a concentration of 100 nM. It was allowed to activate factor VIII for 15 s
(until r - 45 s), when chromogenic substrate for factor Xa (400 pM) and
c-NAPAP (1 irM) were added The course of absorbance in rime was
measured upon addition of factor X (0.33 pM) after another l0 s (at
t : 55 s). On the vertical axis are the values of the quadratic coefficient
(QC) of the equation describing rhe absorbance timi curves (Vz . k2 . f([VIIIa]), see eq. III). They were obtained using a quadratic least squares
fit procedure. The concentration of VIII in the plasma was varied by
mixing pooled normal plasma with hemophilia A plasma
tenase complex and chromogenic substrate conversion are two
concurrent processes.
The following equations describe these simultaneous reactions
in the mixture:
0 1 2 3
T ime  (m in )
Flg.4 Specificity of the factor VIIIa assay in thromboplastin activated
plasma. 10 pl of a 1 in 18 dilution of thromboplastin in a 767 mM CaCl2
solution were addcd to 90 pl of defibrinated plasma (final dilution of 1 in
180). At various times, a sample of this mixture was diluted 1 in 90 in a
cuvctte containing factor IXa (100 nM) (closed circles) or no factor IXa
(open circles), PL (20 pM), Ca2+ (5 mM) and o-NAPAP (1 pM) in butTer,
so as to obtain a final dilution of the plasma of 1 in 100 After 10 s,
factor Xa chromogenic substrate was added, to a concentration of
400 pM. After another 10 s, factor X (0.33 pM) was added ro initiate the
activation reaction, and absorbance was measured during 2 min Factor
VIIIa concentrations are plotted as a percentagc of the total factor VIII
level
after the addition of factor X. The experiment, performed with
pooled normal plasma, hemophilia A plasma, euglobulin solution
or buffer, resulted in absorbance-time curves that were nearly
identical (less than 3% deviation at 5 min). This indicates that all
reactions of factor Xa, except for the amidolysis of the
chromogenic substrate, were indeed effectively inhibited.
Standard Curve
For the concentrations used, i.e. factor IXa 100 nM, PL
20 pM and factor VIIIa less than 50 pM, the amount of complete
tenase that is formed is expected to depend only on the
concentration of factor VIIIa, since published apparent K6 values
for factor IXa on a mixture of phospholipid and factor VIIIa are
below 10 nM (21, 27). Ov strategy to establish this was first to
find a way to stabilize factor VIIIa, so that all factor VIII in a
plasma sample could be activated without inactivation going on
simultaneously. Then the concentration of factor VIIIa could be
varied simply by varying the factor VIII concentration by way of
mixing normal plasma with hemophilia A plasma, and adding
thrombin to this mixture.
Purified factor VIIIa has been found to be stabilized by
complex formation with factor IXa on a negatively charged
phospholipid surface in the presence of Ca2+ (32). It turned out
that stability of VIIIa was achieved for about 20 s when plasma
was diluted first in a mixture of factor IXa, PL, and Ca2+, and
then activated with a large amount of thrombin (100 nM) (Fig. 2).
Fig.2 also shows that the level of the quadratic coefficient did
not increase when the double amount (200 nM) of thrombin was
used, indicating that all the factor VIII had indeed been acti-
vated.
Plasma samples with different factor VIII concentrations were
obtained by mixing pooled normal plasma and hemophilia A
plasma in various ratios. The factor VIII in these samples was
75
bs
!
= C U
LL
25
c{
d[xa]/dr : /([vttla])
dAldt :  k2.[Xa]
"A" being "absorbance", and 'f([VIIIa])", "a function
factor VIIIa concentration".
These equations resolve in:
A(t) : 4o + k2'[Xa]0' t t 1/z' k2' f(vIIIal)' P
(r)
(II)
of the
(rr)
"Al' and "[Xu]g" being "absorbance at time zero" and "fac-
tor Xa concentration at time zero" resDectivelv.
The quadratic coefficient (y2.k2.fliV[ta])). which is a func-
tion of the factor VIIIa concentration, can easily be obtained
from the absorbance-time curve using a simple quadratic least
squares fit procedure. The value of k2 @q.II) was found to be
170 mA./nM. This is in accordance with reported values for Km
andtr/-u" of 142 pMand230 mAmin 1nM-l (23),and,asubstrate
concen l ra t ion  o f  400 uM.
In practice, the course of absorbance in time was determined
using the following general scheme: A sample from the mixture
being assayed wa-s diluted in a cuvette containing IXa (100 nM),
PL (20 pM), Ca2+ (5 mM) and a-NAPAP (1pM). After 10 s,
chromogenic substrate for factor Xa was added, ro a concentra-
tion of 400 pM. Factor X activation was started after another 10 s
by addition of factor X to a concentration of 0.33 pM (concentra-
tions were obtained after all additions had been made). The
course of the absorbance in time was then measured at 405 nm.
The influence of factor Xa in this system was again investigated
by adding a small quantity (1 nM) of factor Xa to the factor X
activating mixture. This was carried out essentially as described in
the general scheme above, but with factor Xa (1 nM) added 10 s
+JZ
o
O
O
o
o
\ .
completely activated as described above. The chromogenic sub_
strate for factor Xa and o-NAPAp were added at 45 s, that is 15 s
af ter  thrombin addi t ion.
Fig.3 shows that /([VIIla]) is linearly proportional to VIIIa
concentrations ranging from 0 to 100% of factor VIIIa in pooled
normal plasma. This reduces equation (I) to
activation of tactor X. In a method used for determining factor
VIIIa concentrations this effect has to be carefully avoided, since
it renders factor Xa concentrations not solely dependent on VIIIa
but also on non-activated factor VIII (Fig. 1). The possibility that
thrombin activates factor VIII in our experiments was excluded
by replacing hirudin, in a large excess over thrombin, for the
somewhat less potent thrombin inhibitor o-NApAp. Althoush
factor Xa is also reported to exhibit feedback activation ;f
factor X (22), this could not be demonstrated in our system.
As shown in Fig. 1, there is another phenomenon to be
considered if one wishes to measure factor VIIIa concentrations
in a plasma sample. Anti-proteases from plasma that is diluted up
to 100-fold are still able to neutralize factor Xa to a quitl
considerable extent. Thus factor Xa concentrations would ilso
depend on the anti-Xa potential of plasma, a parameter that can
be influenced by a variety of antithrombotic drugs.
Since these "side reactions', involve the active site of fac_
tor Xa, the obvious way to suppress them would be an inhibition
of this active site. The conversion of chromogenic substrate
should not be affected, however. It is shown in Fig.2 that this
could be accomplished by a high concentration of chromogenic
substrate for factor Xa. Factor Xa, then, is inhibited and meas_
ured in the same time.
Now, the course of absorbance in time is the result of two
simultaneous reactions, the activation of factor X, and the
amidolysis by factor Xa of chromogenic substrate. The latter
reaction can initially be considered to be of first order, until an
absorbance value of about 0.400 O. D. units.
In case of linearity between amidolysis and factor Xa concen_
tration, the first derivative of the absorbance-time curve, d,4/d/, is
a function only of the other reaction going on in the mixture, viz.
factor X activation in time by the tenase complex (eq. I). In all
experiments performed, with activated factor VIII ranging from 0
to 100%, factor X activation was linear in time for at least 1 min.
Care was taken to use only that part of the absorbance-time curve
for parameter estimation (eqs.III and V).
Lollar et al. have shown that purified porcine factor VIIIa is
markedly stabilized by factorlXa, pC:pS vesicles, and Caz+,
which prolong the half-life time from 7 min to about t h (32). As
thrombin-activated factor VIII in plasma is much more unstable
than its purified counterpart, so is factor VIIIa in plasma that is
diluted 1 in 100 in a mixture containing factor IXa, phospholipid
and Ca2+. It is stable for about 25 s, bui this is followeO Uv a raola
decrease, with a 50% reduction in no more than 3 min. The
question about the cause of this difference in stability of native
compared to purified VIIIa remains unanswered. It seems
unlikely that protein C is activated in our system, as throm_
bomodulin is not present in plasma. Furthermore, it is reported
that loss of cofactor activity of factor'WIIa does not have to be
to reliably vary the factor VIIIa concentration in order to
determine just how factor X activation is a function of factor
VIIIa concentration. The observed linearity is in agreement with
published apparent K6 values for the tenase compiex, which are
lower than l0 nM (21, 27), so that factor IXa in a concentration
of 100 nM is predicted to saturate factor VIIIa in concentrations
that prevail in our system (0-50 pM). Wagenvoord (23) showed
that factor IXa at concentrations higher than 50 nM binds factor
VIIIa optimally in a similar system.
The method we arrived at does in fact not measure factor VIIIa
concentrations per se, but rather factor X activating activity. By
choosing the proper conditions, it was made specific for factoi_
/([vIIIa]) : fr1 . [VIIIa] (IV)
so that equation (III) becomes:
A( t1  :  4o  +  k2 . [Xa]o  . t  t  r / z .h .k r . [v I I Ia ] .?  
ry )
The value of Vz..fu.k2was found to be 1.164 + 0.011 (S. E.) mA
min 2 %VII la-l .  Assumingl00% VIII  to be 1nM (T,3\, and
using a value of 170 mA/nM for ft2 (as previously mentioned), k1
is estimated to be 137 min-1 .(nM Xa/nM vIIIa).
Specificity of the Assay
Aspecificity of the factor VIIIa assay can be introduced at two
levels: conversion of chromogenic substrate by anything other
than factor Xa generated in the assay mixture, and activition of
factor X in the assay mixture by anything other than the IXa_
A small amount of aspecific activation of factor X is of course
expected to be caused by factor IXa which is not complexed to
factor VIIIa. Since the assay is intended to measure factor VIIIa
concentrations in a plasmatic environment, aspecific activation of
factor X in the assay mixture may also .orn" f.orn the extrinsic
factor X activator, the complex of tissue factor with factor VIIa.
The specificity of the factor VIIIa assay scheme was tested
using buffer, non-activated plasma and thromboplastin (final
dilution 1 in 180) activated plasma. This dilution of ihromboplas_
tin clotted uninhibited, non-defibrinated plasma in 70 s. Wllen we
employed the general scheme described ibove to measure factor
VIIIa activity in buffer and non-activated plasma, identical
control values for the quadratic coefficient of 0.6 mA/min2 were
found. Als already mentioned, this value is the result of the slow
activation of factor X by lXa in the presence of phospholipid and
Ca2*, but without factor VIIIa.
In order to be able to determine any aspecificity in thrombo_
plastin activated plasma, we suppressed the factor VIIIa based
values obtained in the absence of factor IXa were so low, that a
quadratic curve could not reliably be fitted to the experimental
absorbance-time data. Instead, we made an estimation of the
maximal values of the quadratic coefficient by assuming the
constant and linear coefficient to be zero, and calculatine the
quadratic coeff icient from 1/z.kt.kz.[Vl l la] :  A(t) l l  ul  t  :
2 min.
Discussion
Although thrombin seems to be the only physiological
activator (4), factor Xa was shown to be able to activate
factor VIII in purified systems (lg-2I). Factor X activated in a
system containing factor IXa, factor VIII, phospholipid and Ca2+
causes generation of factor vl I Ia that in turn wil l  aicclerate the
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